Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD Clinical research trials and Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD. Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD clinical trial. Test subjects typically receive the most effective healthcare possible for their Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD



Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

For Condition: Acute Graft Versus Host Disease
Status: Terminated
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: Phase II efficacy evaluation, phase I/II efficacy and toxicity trial of recombinant human keratinocyte growth factor for the treatment of steroid refractory gastrointestinal graft versus host disease.
Details: There are two processes that cause diarrhea as the clinical manifestation of graft versus host disease. The first is the obvious immunologic attack on the colonic epithelium of the recipient. Once this immunologic attack has been abated the recipient is left with a colonic mucosa that is devoid of microvilla and has a smooth intestinal boarder. This is frequently subject to superinfections from bacteria all of which cause the diarrhea to continue. Our only endpoint to measure clinical response of immunosuppression is the resolution of diarrhea. The human recombinant keratinocyte growth factor stimulates the growth of colonic epithelium. The growth of colonic epithelium will in turn probably ameliorate some of the diarrhea associated with graft versus host disease.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: - Patients post allogeneic bone marrow transplant with watery diarrhea progressed on 2mg/kg of steroids after 3 days or failed to improve after 5 days. - Patients may have skin or liver involvement with graft versus host disease. - Patients should not have any infections etiology for diarrhea.
Total Enrollment: 25

Location and Contact Information:

MD Anderson Cancer Center
Houston,  Texas,  77030
United States
 


Additional Information:
Study ID Numbers:  ID00-036; 
Study Start Date: October 2000
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038792

Other Acute Graft Versus Host Disease Studies:
1. Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

2. Dose-finding study using pentostatin for injection in the treatment of steroid-refractory aGvHD

Related Studies:

Other Acute Graft Versus Host Disease Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Phase I/II trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
Modify your Search

  Other Acute Graft Versus Host Disease Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103